Abstract
Cancer patients are at risk for a more severe COVID-19 infection as well as an adverse outcome of such infection. This may be caused by the cancer itself (e.g haematological malignancies and lung cancer) or due to immune suppression caused by anti-cancer treatment. Severe COVID-19 infections are often complicated by a coagulopathy that clinically results in a high incidence of venous thromboembolic disease. Cancer itself is associated with a hypercoagulable state and a markedly increased incidence of thromboembolic complications, hence the combination of cancer and COVID-19 may amplify this risk. COVID-19 vaccination seems safe and effective in most cancer patients although adapted and bespoke vaccination schemes may increase the seroconversion rate and immune response in selected patients. Specific management strategies to improve outcomes of cancer patients in COVID-19 (e.g. higher intensity antithrombotic prophylaxis) are lacking and should be evaluated in clinical studies simultaneously focusing on efficacy and safety.
【저자키워드】 COVID-19, SARS-CoV-2, thrombosis, D-dimer, Coagulation, Pulmonary embolism, Disseminated intravascular coagulation, thrombotic microangiopathy, 【초록키워드】 immune response, vaccination, Cancer, Infection, risk, outcome, lung cancer, Coagulopathy, adverse outcome, Prophylaxis, COVID-19 vaccination, COVID-19 infection, management, Patient, Efficacy and safety, incidence, anti-cancer treatment, disease, patients, Immune suppression, clinical study, Combination, Antithrombotic, Safe, cancer patient, hypercoagulable, intensity, Severe COVID-19 Infection, seroconversion rate, thromboembolic complications, Specific, venous thromboembolic, haematological malignancy, effective, IMPROVE, selected, caused, clinically, evaluated, amplify, 【제목키워드】 Cancer, Coagulopathy,